title: Cytokeratin 7/20 and mucin core protein expression in ulcerative colitis-associated colorectal neoplasms.
abstract: Different histogenetic pathways have been suggested between ulcerative colitis (UC)-associated neoplasia and sporadic colorectal neoplasia. Little is known about the cytokeratin (CK) and mucin expression in UC-associated neoplasms. To clarify the characteristics of UC-associated colorectal carcinogenesis, we examined the immunohistochemical expression of CK7, CK20, MUC2, MUC5AC and MUC6 in 90 colorectal neoplasms, including 22 UC-associated adenocarcinomas (colitic cancer; CC), ten high-grade dysplasias (HGD) in UC, nine low-grade dysplasias (LGD) in UC, 24 sporadic tubular adenomas (TA) and 25 adenocarcinomas (AC). CK7 was positive in most of UC-associated neoplasms: 59% of CC cases, 80% of HGD and 89% of LGD, respectively, whereas, in non-UC associated neoplasia, 21% of TA and 12% of AC. The frequency of MUC6 expression in UC-associated neoplasia was 32% in CC, 30% in HGD and 44% in LGD, respectively, whereas, in non-UC associated neoplasia, 4.2% in TA and 0% in AC. MUC5AC expression in UC-associated neoplasia was detectable in 73% of CC, 90% of HGD and 89% of LGD, respectively; in non-UC associated neoplasia 67% in AC and 20% in TA. There were obvious differences in the expression of CK7 and MUC6 between UC-associated neoplasms and sporadic tumors. The incidence of MUC5AC expression in UC-associated neoplasms was also higher than sporadic tumors. These results suggest that gastric-type mucins play an important role in the initial step of CC-tumorigenesis, and CK7 and gastric-type mucins may be useful in the differential diagnosis between UC-associated neoplasms and sporadic ones.
authors.affiliation: Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kamigyo-ku, 602-8566 Kyoto, Japan.
authors.forename: Natsuko
authors.initials: N
authors.lastname: Tatsumi
authors.forename: Ryoji
authors.initials: R
authors.lastname: Kushima
authors.forename: Michael
authors.initials: M
authors.lastname: Vieth
authors.forename: Ken-Ichi
authors.initials: K
authors.lastname: Mukaisho
authors.forename: Rie
authors.initials: R
authors.lastname: Kakinoki
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Okabe
authors.forename: Franz
authors.initials: F
authors.lastname: Borchard
authors.forename: Manfred
authors.initials: M
authors.lastname: Stolte
authors.forename: Takeshi
authors.initials: T
authors.lastname: Okanoue
authors.forename: Takanori
authors.initials: T
authors.lastname: Hattori
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D000236:Adenoma / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D014408:Biomarkers, Tumor / Q000378:metabolism; D003093:Colitis, Ulcerative / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D015179:Colorectal Neoplasms / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D019085:Fluorescent Antibody Technique, Direct; D006801:Humans; D007124:Immunoenzyme Techniques; D053554:Keratin-20; D053552:Keratin-7; D007633:Keratins / Q000378:metabolism*; D009077:Mucins / Q000378:metabolism*; D011230:Precancerous Conditions / Q000378:metabolism / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; C507499:KRT20 protein, human; C507497:KRT7 protein, human; D053554:Keratin-20; D053552:Keratin-7; D009077:Mucins; D007633:Keratins